Incretin mimetics administered by auto-injectors or pens enable significant weight reduction and offer an important means of ...

Eli Lilly & Co.’s Inc.’s stock soared 13% in premarket trade Thursday, after the drug maker reported positive results from a late-stage trial of an oral GLP-1 treatment for Type 2 diabetes. The ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients ...

In this video, Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA, discusses notable updates across several areas of cardiology ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

The growing prevalence of diabetes, primarily due to obesity, aging populations, and sedentary lifestyles, is a key factor ...

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Linda Gigliotti, MS, RDN, CDCES, FAND, about combining the use of GLP-1 ...

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

The rising prevalence of obesity has prompted the development of effective weight loss treatments. Several peptide hormones have a key role in appetite regulation and metabolism, but the discovery ...

New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

Citation: Study suggests lean muscle mass loss can be minimized during weight loss therapy using newer incretin obesity drugs (2025, April 10) retrieved 20 April 2025 from https://medicalxpress ...